臨床神経学
Online ISSN : 1882-0654
Print ISSN : 0009-918X
ISSN-L : 0009-918X
シンポジウム4:アルツハイマー病の診断と治療開発
シンポジウム4―4 アルツハイマー病の診断と治療開発 アルツハイマー病のワクチン療法
田平 武
著者情報
ジャーナル フリー

2009 年 49 巻 11 号 p. 848-850

詳細
抄録

Since AN-1792 vaccine induced autoimmune encephalitis, several pharmaceutical companies are now concentrated in developing antibody therapy in Alzheimer's disease (AD). Each antibody has own characteristics. Thus, it is unpredictable at present which antibody is the most beneficial until we see the result of clinical trials. If disease modifying antibodies were found, they will be widely used for treatment of AD in near future. As a candidate of such antibodies, we have developed TAPIR-like antibody with much higher affinity to Aβ42 than Aβ40, and it effectively deleted senile plaque amyloid and Aβ oligomers without increasing microhemorrhages. Although passive immunization can avoid autoimmune encephalitis, it is expensive and it is not suitable for prevention. Thus, safe vaccines by active immunization would be better. Vaccines that induce Th2 type immune responses such as oral vaccine or per-nasal vaccine would be promising.

著者関連情報
© 2009 日本神経学会
前の記事 次の記事
feedback
Top